AssetMemo
AssetsMechanismsCompaniesCalendarChartsWatchlistAsk AIMethodology
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
◧AssetMemo
⌕

Evidence-graded drug-asset intelligence
◧AssetMemo
AssetsMechanismsCompaniesReadout CalendarCompare ChartsWatchlist & AlertsAsk AI
Therapeutic areas
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
ReferenceMethodology & RubricUs vs. AI ToolsUK IBD Access GuideAbout the founder

Educational data tool. Evidence graded; securities never are.

BrowseAll assetsAll mechanismsAll companiesReadout calendarReadouts by yearResults by diseaseDelayed readoutsOpen dataCompare share pricesWhat's new
ReferenceMethodology & sourcesUs vs. the AI toolsUK IBD Access GuideAbout the founderAsk the AIReport a problem / suggest a feature

Educational research only, not investment advice. Evidence quality is graded; securities never are. · Terms · Privacy · Logos by Logo.dev

Ask

Opening the console…

1,457 drug developers and their pipelines

Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.

Lists by late-stage drug kind: biologics, small molecules, cell and gene therapies, RNA and oligonucleotide drugs, peptide drugs.

← browse by therapeutic area

Views

1457 of 1457 companies

CompanyPipelineMost advancedNext readoutMarket capCash & inv.RunwayR&D / yr
Abbisko Therapeutics logo
Abbisko Therapeutics2256 · HKEX
3 assets: 2 Ph 2, 1 Ph 1LavengratinibPhase 2 · Non-Small Cell Lung CancerMar 2027ABSK112 · Phase 1—$286MDec 2025—$71M
Actinogen Medical (ASX: ACW) logo
Actinogen Medical (ASX: ACW)ACW · ASX
1 asset: 1 Ph 3EmestedastatPhase 2/3 · Alzheimer's DiseasePartial signalNone on record——Ended Aug 2025Jun 2025~$6.0M
A
Active Biotech ABACTI · Nasdaq Stockholm
1 asset: 1 Ph 2Naptumomab estafenatoxPhase 2 · Non-Small Cell Lung CancerWeak signal1 Mar 2027Naptumomab estafenatox · Phase 1————
AdAlta logo
AdAlta1AD · ASX
1 asset: 1 Ph 1AD-214Phase 1 · Chronic Kidney DiseaseWeak signalNone on record—$0.9MJun 2025Ended Jul 2025—
Adocia logo
AdociaADOC · Euronext Paris
1 asset: 1 Ph 3THDB0206Phase 3 · Type 2 DiabetesPartial signalNone on record————
Agomab Therapeutics NV logo
Agomab Therapeutics NVAGMB · Nasdaq
1 asset: 1 Ph 2ontunisertibPhase 2 · Fibrostenosing Crohn's DiseaseNone on record————
Ahn-Gook Pharmaceutical logo
Ahn-Gook Pharmaceutical001540 · KOSDAQ
2 assets: 2 Ph 3AG2304Phase 3 · Atherosclerotic Cardiovascular DiseasePartial signalNone on record———~$14M
Akeso logo
Akeso9926 · HKEX
12 assets: 1 approved, 6 Ph 3, 5 Ph 2IvonescimabPhase 3 · Non-Small Cell Lung CancerReliable signalNov 2026Cadonilimab · Phase 3—$1.0BDec 2024~14.1 qtrs$166M
Aktis Oncology, Inc. logo
Aktis Oncology, Inc.AKTS ·
2 assets: 2 Ph 1AKY-1189Phase 1 · Non-Small Cell Lung CancerDec 2027AKY-2519 · Phase 1—$494MSep 2026~23.0 qtrs~$94M
Alar Pharmaceuticals logo
Alar Pharmaceuticals6785 · TPEx
1 asset: 1 Ph 1ALA-3000Phase 1 · Major Depressive DisorderPartial signalNone on record————
Alebund Pharmaceuticals logo
Alebund Pharmaceuticals9637 · HKEX
1 asset: 1 Ph 3AP301 (fiber-iron phosphate binder)Phase 3 · Chronic Kidney DiseasePartial signalNone on record———$52M
Aligos Therapeutics logo
Aligos TherapeuticsALGS · Nasdaq
1 asset: 1 Ph 2ALG-055009Phase 2 · MASH / NASHNone on record—$32MSep 2026~1.9 qtrs$83M
ALK-Abelló logo
ALK-AbellóALK B · Nasdaq Copenhagen
1 asset: 1 approvedApproved assets onlyApr 2027Epinephrine · Approved————
Alkem Laboratories logo
Alkem LaboratoriesALKEM · NSE
1 asset: 1 Ph 3EvogliptinPhase 3 · Type 2 DiabetesReliable signalNone on record————
Alkermes plc logo
Alkermes plcALKS · Nasdaq
6 assets: 5 approved, 1 Ph 3AlixorextonPhase 3 · NarcolepsyNov 2026Alixorexton · Phase 2—$755MSep 2026Cash-flow positive$430M
Allist Pharmaceuticals logo
Allist Pharmaceuticals688578 · SSE STAR Market
4 assets: 3 Ph 3, 1 Ph 1GlecirasibPhase 3 · Non-Small Cell Lung CancerWeak signalDec 2026AST2303 · Phase 1———$75M
A
AlmirallALM · BME
5 assets: 3 approved, 1 Ph 3, 1 otherAlmotriptan (Axert)US approval withdrawn · MigraineWeak signal25 Apr 2027lebrikizumab · Phase 3—$405MJun 2026——
Alpha Compute Corp logo
Alpha Compute CorpALP · Nasdaq
2 assets: 2 Ph 2TT-10Phase 1/2 · Non-Small Cell Lung Cancer1 Dec 2028TT-10 · Phase 1/2—$0.2MSep 2025Ended Oct 2025~$5.4M
Alphamab Oncology logo
Alphamab Oncology9966 · HKEX
4 assets: 2 Ph 3, 2 Ph 2Anbenitamab repodatecanPhase 3 · HR+/HER2- Metastatic Breast Cancer30 Dec 2026Anbenitamab repodatecan · Phase 3—$193MDec 2025~12.2 qtrs~$70M
Alteogen Inc. logo
Alteogen Inc.196170 · KOSDAQ
1 asset: 1 otherAflibercept (Eyluxvi)Age-Related Macular DegenerationNone on record————
Alvotech logo
AlvotechALVO · Nasdaq
4 assets: 2 approved, 2 otherAflibercept (Afiveg)Age-Related Macular DegenerationNone on record—$172MDec 2025~26.3 qtrswith a later raise$184M
AlzeCure Pharma logo
AlzeCure PharmaALZCUR · Spotlight Stock Market
1 asset: 1 Ph 1ACD856Phase 1 · Alzheimer's DiseasePartial signalNone on record————
Alzinova AB logo
Alzinova ABALZ · Nasdaq First North
1 asset: 1 Ph 1ALZ-101Phase 1 · Alzheimer's DiseasePartial signalNone on record————
Amneal Pharmaceuticals logo
Amneal PharmaceuticalsAMRX · NYSE
6 assets: 6 approvedApproved assets onlyNone on record—$180MSep 2026Cash-flow positive$181M
Amphastar Pharmaceuticals, Inc. logo
Amphastar Pharmaceuticals, Inc.AMPH · Nasdaq
4 assets: 4 approvedApproved assets onlyNone on record—$231MSep 2026Cash-flow positive$92M
Anbogen Therapeutics, Inc. logo
Anbogen Therapeutics, Inc.7784 · TPEx
1 asset: 1 Ph 2GozanertinibPhase 1/2 · Non-Small Cell Lung CancerNov 2026Gozanertinib · Phase 1/2————
AnGes logo
AnGes4563 · TSE
1 asset: 1 Ph 3Beperminogene perplasmid (HGF plasmid)Phase 3 · Atherosclerotic Cardiovascular DiseaseNone on record—$12MDec 2025Ended Feb 2026$24M
ANI Pharmaceuticals, Inc. logo
ANI Pharmaceuticals, Inc.ANIP · Nasdaq
4 assets: 4 approvedApproved assets only18 Dec 2029Anastrozole · Phase 3—$421MSep 2026Cash-flow positive$51M
Antengene Corporation Limited logo
Antengene Corporation Limited6996 · HKEX
2 assets: 1 approved, 1 Ph 2OnatasertibPhase 2 · Non-Small Cell Lung CancerWeak signalDec 2026Selinexor · Phase 2/3—$111MJun 2025~21.0 qtrs~$22M
Anterogen logo
Anterogen065660 · KOSDAQ
1 asset: 1 Ph 2ALLO-ASCPhase 2 · Dystrophic Epidermolysis BullosaWeak signalNone on record————
AP Biosciences Inc. logo
AP Biosciences Inc.6945 · TPEx
2 assets: 2 Ph 2B1962Phase 2 · Non-Small Cell Lung CancerDec 2026AP203 · Phase 1/2————
ApicHope Pharmaceutical Group Co., Ltd. (formerly Yipinhong Pharmaceutical Co., Ltd.) logo
ApicHope Pharmaceutical Group Co., Ltd. (formerly Yipinhong Pharmaceutical Co., Ltd.)300723 · SZSE
1 asset: 1 Ph 2MetacavirPhase 2 · Chronic Hepatitis BNone on record————
A
AprilBio397030 · KOSDAQ
1 asset: 1 Ph 2EVO301Phase 2 · Atopic DermatitisPartial signalNone on record————
Aptabio Therapeutics logo
Aptabio Therapeutics293780 · KOSDAQ
1 asset: 1 Ph 2IsuzinaxibPhase 2 · Type 2 DiabetesPartial signal30 Jun 2027Isuzinaxib · Phase 2————
A
Arctic BiosciencePrivate
1 asset: 1 Ph 2HRO350Phase 2 · PsoriasisNone on record————
Arecor Limited logo
Arecor LimitedAREC · AIM
1 asset: 1 Ph 1Insulin aspart (AT278)Phase 1 · Type 2 DiabetesPartial signalNone on record————
argenx logo
argenxARGX · Nasdaq
2 assets: 2 approvedApproved assets onlyNone on record—$702MDec 2023——
Artgen Biotech logo
Artgen BiotechABIO · MOEX
1 asset: 1 Ph 3NeovasculgenPhase 2/3 · Atherosclerotic Cardiovascular DiseasePartial signalNone on record————
Asahi Kasei Corporation logo
Asahi Kasei Corporation3407 · TSE
2 assets: 1 approved, 1 Ph 2SetanaxibPhase 2 · Primary Biliary CholangitisPartial signalMar 2027Budesonide (targeted-release) · Approved————
Ascendis Pharma A/S logo
Ascendis Pharma A/SASND · Nasdaq
2 assets: 2 approvedApproved assets onlyAug 2027palopegteriparatide · Phase 3—$724MDec 2025Cash-flow positive$344M
Ascentage Pharma Group Inc. logo
Ascentage Pharma Group Inc.AAPG ·
5 assets: 3 Ph 3, 1 Ph 2, 1 Ph 1LisaftoclaxPhase 3 · Acute Myeloid LeukemiaWeak signalDec 2026Lisaftoclax · Phase 2—$122MDec 2024~31.6 qtrs$132M
Ascletis Pharma logo
Ascletis Pharma1672 · HKEX
4 assets: 3 Ph 3, 1 Ph 1DenifanstatPhase 3 · Recurrent GlioblastomaReliable signalDec 2026Envafolimab · Phase 2—$206MDec 2025~4.1 qtrs$57M
Asieris Pharmaceuticals logo
Asieris Pharmaceuticals688176 · SSE STAR Market
1 asset: 1 Ph 1NepicastatPhase 1 · Ulcerative ColitisWeak signalNone on record—$91MMar 2026~5.6 qtrs$49M
Astellas Pharma logo
Astellas Pharma4503 · TSE
15 assets: 4 approved, 4 Ph 3, 4 Ph 2, 3 Ph 1RoxadustatPhase 3 · Chronic Kidney DiseaseReliable signal30 Dec 2026ASP546C · Phase 1/2—$1.8BMar 2026—$2.1B
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH · Nasdaq
2 assets: 1 approved, 1 Ph 2aritinerceptPhase 1/2 · Generalized Myasthenia Gravis2 Mar 2029aritinercept · Phase 1/2—$487MSep 2026Cash-flow positive$48M
Bayer logo
BayerBAYN · Xetra
21 assets: 12 approved, 3 Ph 3, 3 Ph 2, 1 Ph 1, 2 otherMiglitolUS approval withdrawn · Type 2 DiabetesPartial signalDec 2026Mosliciguat · Phase 2—$6.6BMar 2026Ended Aug 2026~$6.6B
BeBetter Med logo
BeBetter Med688759 · SSE STAR Market
4 assets: 2 Ph 3, 2 Ph 2IfupinostatPhase 3 · Relapsed/Refractory Diffuse Large B-Cell LymphomaWeak signalJun 2027BEBT-109 · Phase 2—$144MDec 2025~6.7 qtrs$17M
Beijing Biostar Pharmaceuticals logo
Beijing Biostar Pharmaceuticals2563 · HKEX
1 asset: 1 Ph 3UtidelonePhase 3 · Non-Small Cell Lung CancerPartial signal1 Dec 2026Utidelone · Phase 2————
Beijing InnoCare Pharma Tech Co. logo
Beijing InnoCare Pharma Tech Co.9969 · HKEX
5 assets: 1 approved, 3 Ph 3, 1 Ph 2FadeucravacitinibPhase 3 · PsoriasisPartial signal25 Nov 2026Soficitinib (ICP-332) · Phase 3—$1.1BMar 2026Profitable~$132M
Betta Pharmaceuticals Co. logo
Betta Pharmaceuticals Co.300558 · SZSE ChiNext
9 assets: 1 approved, 3 Ph 3, 3 Ph 2, 2 Ph 1BefotertinibPhase 3 · Non-Small Cell Lung CancerPartial signalDec 2026BPI-371153 · Phase 1——Profitable—
BicycleTx Limited logo
BicycleTx LimitedBCYC · Nasdaq
2 assets: 2 Ph 2Nuzefatide pevedotinPhase 2 · Pancreatic Ductal Adenocarcinoma31 Dec 2026Nuzefatide pevedotin · Phase 1/2—$470MSep 2026~10.7 qtrs$175M
Bio-Path Holdings, Inc. logo
Bio-Path Holdings, Inc.BPTH · OTC
2 assets: 1 Ph 2, 1 Ph 1PrexigebersenPhase 2 · Acute Myeloid LeukemiaWeak signalMar 2027BP1002 · Phase 1—no price since 18 Aug 2026<$0.1MMar 2026Ended Apr 2026$8.1M
Bio-Thera Solutions logo
Bio-Thera Solutions688177 · SSE STAR Market
7 assets: 3 approved, 2 Ph 3, 1 Ph 2, 1 Ph 1BAT3306Phase 3 · Non-Small Cell Lung CancerPartial signal31 Dec 2026Vedastotug · Phase 1/2————
BioArctic AB logo
BioArctic ABBIOA B · Nasdaq Stockholm
1 asset: 1 Ph 2exidavnemabPhase 2 · Parkinson's DiseaseWeak signalNone on record————
BioAtla, Inc. logo
BioAtla, Inc.BCAB · OTC
3 assets: 3 Ph 2Ozuriftamab vedotinPhase 2 · Head and Neck Squamous Cell CarcinomaPartial signalNone on record—no price since 28 Aug 2026$1.5MJun 2026Ended Jul 2026$25M
Biocon logo
BioconBIOCON · NSE
3 assets: 2 approved, 1 Ph 1ItolizumabPhase 1 · PsoriasisNone on record—$259MMar 2026—$111M
BioInvent International AB logo
BioInvent International ABBINV · Nasdaq Stockholm
1 asset: 1 Ph 2BI-1910Phase 1/2 · Non-Small Cell Lung Cancer14 Jul 2027BI-1910 · Phase 1/2—no price since 25 Sep 2026———
BioXcel Therapeutics, Inc. logo
BioXcel Therapeutics, Inc.BTAI · OTC
1 asset: 1 Ph 3Dexmedetomidine (Igalmi)Phase 3 · SchizophreniaReliable signal31 Jul 2027Dexmedetomidine (Igalmi) · Phase 1—no price since 4 Sep 2026$14MJun 2026Ended Oct 2026$22M
Black Diamond Therapeutics, Inc. logo
Black Diamond Therapeutics, Inc.BDTX ·
1 asset: 1 Ph 2SilevertinibPhase 1/2 · Non-Small Cell Lung CancerMar 2028Silevertinib · Phase 1/2—$103MSep 2026~12.3 qtrs$28M
Boryung Pharmaceutical logo
Boryung Pharmaceutical003850 · KOSPI
1 asset: 1 Ph 3Fimasartan/atorvastatin/ezetimibe (BR1017)Phase 3 · HypertensionPartial signalNone on record—$170MMar 2026—$38M
Bright Minds Biosciences Inc. logo
Bright Minds Biosciences Inc.DRUG · Nasdaq
1 asset: 1 Ph 2BMB-101Phase 2 · EpilepsyNov 2026BMB-101 · Phase 2—$4.2MSep 2024~12.4 qtrs$0.9M
BrightGene Bio-Medical Technology logo
BrightGene Bio-Medical Technology688166 · SSE
2 assets: 1 Ph 3, 1 Ph 2BGM0504Phase 3 · ObesityPartial signal28 Feb 2027BGM0504 · Phase 2———$83M
BrightPath Biotherapeutics Co., Ltd. logo
BrightPath Biotherapeutics Co., Ltd.4594 · TSE
1 asset: 1 Ph 1BP2202Phase 1 · Multiple Myeloma31 Dec 2027BP2202 · Phase 1—$14MMar 2026~6.3 qtrs—
B
Brii Biosciences2137 · HKEX
1 asset: 1 Ph 3Tobevibart (VIR-3434)Phase 3 · Chronic Hepatitis DeltaDec 2026Tobevibart (VIR-3434) · Phase 3————
Can-Fite BioPharma logo
Can-Fite BioPharmaCANF · Nasdaq
2 assets: 2 Ph 3NamodenosonPhase 3 · Hepatocellular CarcinomaPartial signal31 Aug 2027Piclidenoson · Phase 2—$8.5MDec 2025Ended Mar 2026$6.7M
Cantargia AB logo
Cantargia ABCANTA · Nasdaq Stockholm
1 asset: 1 Ph 2NadunolimabPhase 1/2 · Non-Small Cell Lung CancerWeak signalNone on record—$24MMar 2026~7.4 qtrs—
CARsgen Therapeutics Holdings Limited logo
CARsgen Therapeutics Holdings Limited2171 · HKEX
2 assets: 2 Ph 2Zevorcabtagene autoleucelPhase 1/2 · Multiple MyelomaWeak signal15 Jun 2027CT071 · Phase 1/2—$203MDec 2024Ended Oct 2026$66M
CASI Pharmaceuticals, Inc. logo
CASI Pharmaceuticals, Inc.CASIF · OTC
2 assets: 1 approved, 1 Ph 2CID-103Phase 2 · Immune ThrombocytopeniaWeak signal30 Nov 2028CID-103 · Phase 2—no price since 18 Aug 2026$5.6MDec 2025Ended Apr 2026$6.3M
Catalyst Pharmaceuticals, Inc. logo
Catalyst Pharmaceuticals, Inc.CPRX · Nasdaq
1 asset: 1 approvedApproved assets only6 Apr 2027Perampanel · Phase 2—no price since 14 Jul 2026———
Celltrion logo
Celltrion068270 · KOSPI
11 assets: 8 approved, 3 Ph 3CT-P44Phase 3 · Multiple MyelomaFeb 2027CT-P51 · Phase 3—$679MDec 2024Profitable—
Celon Pharma logo
Celon PharmaCLN · GPW
2 assets: 2 Ph 2CPL500036Phase 2 · Parkinson's DiseaseReliable signalNone on record————
CERo Therapeutics Holdings, Inc. logo
CERo Therapeutics Holdings, Inc.CERO · OTC
1 asset: 1 Ph 1CER-1236Phase 1 · Acute Myeloid Leukemia31 Dec 2026CER-1236 · Phase 1—no price since 18 Aug 2026$0.7MSep 2026Ended Oct 2026$7.3M
Chengdu Kanghong Pharmaceutical logo
Chengdu Kanghong Pharmaceutical002773 · SZSE
2 assets: 2 Ph 3KH607Phase 3 · Major Depressive DisorderPartial signalDec 2027KH607 · Phase 3———$56M
C
China Medical System867 · HKEX
9 assets: 5 approved, 4 Ph 3DesidustatPhase 3 · Chronic Kidney DiseasePartial signal31 Jan 2027CMS-D001 · Phase 2———$81M
China Resources Double-Crane Pharmaceutical logo
China Resources Double-Crane Pharmaceutical600062 · SSE
1 asset: 1 Ph 3GemigliptinPhase 3 · Type 2 DiabetesReliable signalNone on record————
China Resources Sanjiu Medical & Pharmaceutical logo
China Resources Sanjiu Medical & Pharmaceutical000999 · SZSE
2 assets: 1 Ph 3, 1 otherBGM0504Phase 3 · ObesityPartial signal28 Feb 2027BGM0504 · Phase 2—$666MDec 2025—$241M
Chipscreen Biosciences logo
Chipscreen Biosciences688321 · SSE
4 assets: 2 Ph 3, 1 Ph 2, 1 Ph 1ChidamidePhase 3 · HR+/HER2- Metastatic Breast CancerReliable signal18 Sep 2027CS32582 · Phase 1/2————
Chong Kun Dang Pharmaceutical logo
Chong Kun Dang Pharmaceutical185750 · KOSPI
9 assets: 1 approved, 3 Ph 3, 2 Ph 2, 3 Ph 1CKD-701Phase 3 · Age-Related Macular DegenerationReliable signalDec 2029CKD-703 · Phase 1/2————
Chordia Therapeutics, Inc. logo
Chordia Therapeutics, Inc.Private
1 asset: 1 Ph 2RogocekibPhase 1/2 · Acute Myeloid LeukemiaJun 2028Rogocekib · Phase 1/2—$16MMay 2026—~$21M
Chugai Pharma logo
Chugai Pharma4519 · TSE
14 assets: 10 approved, 2 Ph 3, 1 Ph 2, 1 Ph 1enicepatidePhase 3 · ObesityReliable signal30 Nov 2026Atezolizumab · Phase 3———$1.3B
Cipla logo
CiplaCIPLA · NSE
3 assets: 1 approved, 1 Ph 3, 1 Ph 2VildagliptinPhase 3 · Type 2 DiabetesPartial signalMar 2027Afrezza · Phase 2————
CJ Bioscience, Inc. logo
CJ Bioscience, Inc.311690 · KOSDAQ
1 asset: 1 Ph 2CJRB-101Phase 1/2 · Non-Small Cell Lung CancerNone on record————
Connect Biopharma logo
Connect BiopharmaCNTB · Nasdaq
1 asset: 1 Ph 3RademikibartPhase 3 · Atopic DermatitisPartial signal31 Dec 2026Rademikibart · Phase 3—$31MJun 2026~2.1 qtrs$54M
Consun Pharmaceutical Group logo
Consun Pharmaceutical Group1681 · HKEX
1 asset: 1 Ph 1SK-08Phase 1 · Chronic Kidney DiseaseNone on record—$176MDec 2025——
C
Cosmo N.V.COPN · SIX
2 assets: 2 approvedApproved assets onlyNone on record————
CSPC Pharmaceutical Group logo
CSPC Pharmaceutical Group1093 · HKEX
11 assets: 8 Ph 3, 2 Ph 2, 1 otherPrusogliptinPhase 3 · Type 2 DiabetesReliable signal30 Dec 2026Anbenitamab repodatecan · Phase 3—$1.4BDec 2025—$809M
CStone Pharmaceuticals logo
CStone Pharmaceuticals2616 · HKEX
2 assets: 1 approved, 1 Ph 3SugemalimabPhase 3 · Non-Small Cell Lung CancerReliable signal30 Jul 2027Pralsetinib · Approved—$131MDec 2025Ended Jul 2026$43M
Curacle logo
Curacle365270 · KOSDAQ
2 assets: 2 Ph 2CU01-1001Phase 2 · Chronic Kidney DiseasePartial signalNone on record————
CytoDyn logo
CytoDynCYDY · OTCQB
1 asset: 1 Ph 3LeronlimabPhase 2/3 · HIVPartial signalJan 2028Leronlimab · Phase 2—no price since 18 Aug 2026$16MAug 2026~3.3 qtrs$7.2M
D&D Pharmatech logo
D&D Pharmatech347850 · KOSDAQ
1 asset: 1 Ph 2ZabopegdutidePhase 2 · ObesityPartial signalNone on record————
Daewoong Pharmaceutical logo
Daewoong Pharmaceutical069620 · KOSPI
7 assets: 4 Ph 3, 2 Ph 1, 1 otherEnavogliflozinPhase 3 · Type 2 DiabetesReliable signalNov 2027Enavogliflozin · Phase 3———$155M
Daiichi Sankyo logo
Daiichi Sankyo4568 · TSE
21 assets: 10 approved, 6 Ph 3, 4 Ph 2, 1 Ph 1Denosumab (Xgeva)Phase 3 · Multiple MyelomaReliable signal17 Dec 2026bevacizumab-awwb · Phase 1—$3.1BMar 2026—$3.0B
DexTech Medical AB logo
DexTech Medical ABDEX · Spotlight Stock Market
1 asset: 1 Ph 2ODX (Osteodex)Phase 1/2 · Multiple MyelomaNone on record—$1.6MJun 2025~12.9 qtrs—
Dizal Pharmaceuticals logo
Dizal Pharmaceuticals688192 · SSE STAR Market
2 assets: 1 approved, 1 Ph 2DZD6008Phase 1/2 · Non-Small Cell Lung CancerJun 2027DZD6008 · Phase 1/2—$42MDec 2025Ended Feb 2026$119M
Dong-A ST logo
Dong-A ST170900 · KOSPI
9 assets: 1 approved, 2 Ph 3, 2 Ph 2, 3 Ph 1, 1 otherEvogliptinPhase 3 · Type 2 DiabetesReliable signalDec 2026DA-2811 · Phase 2————
DualityBio Inc. logo
DualityBio Inc.9606 · HKEX
5 assets: 2 Ph 3, 3 Ph 2Trastuzumab pamirtecanPhase 3 · HR+/HER2- Metastatic Breast CancerPartial signalAug 2027Trastuzumab pamirtecan · Phase 1/2————
E
Edding Genor Group Holdings Limited6998 · HKEX
1 asset: 1 Ph 2EDP167Phase 2 · Atherosclerotic Cardiovascular DiseaseWeak signalNov 2027EDP167 · Phase 2——Ended Jun 2024Dec 2023—
Eisai logo
Eisai4523 · TSE
18 assets: 10 approved, 4 Ph 3, 4 Ph 2SerplulimabPhase 3 · Non-Small Cell Lung CancerReliable signal29 Nov 2026Rimegepant (Nurtec ODT) · Phase 3—$1.5BMar 2026—$1.0B
Emmaus Life Sciences logo
Emmaus Life SciencesEMMA · OTCQB
1 asset: 1 approvedApproved assets onlyNone on record—$2.8MJun 2026Cash-flow positive$0.2M
Enanta Pharmaceuticals, Inc. logo
Enanta Pharmaceuticals, Inc.ENTA · Nasdaq
2 assets: 2 Ph 2EDP-323Phase 2 · Respiratory Syncytial Virus InfectionPartial signalDec 2026zelicapavir · Phase 2—$190MJun 2026~18.8 qtrs$93M

Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.

Page123456789101112131415